Advances in In Vivo Models for Immunotoxicity Evaluation

Immunotoxicity refers to any adverse effect on the structure or function of the immune system induced by exposure to chemical substances, biologics, or therapeutic agents. As immunomodulatory drugs, cell-based therapies, and biologics continue to gain momentum in clinical development, evaluating their impact on immune function has become a central aspect of preclinical safety assessment. In vivo models remain indispensable for capturing complex immune responses that cannot be fully replicated in vitro.

Modern in vivo immunotoxicology studies assess both immunosuppression and immunostimulation. Traditional endpoints such as organ weights (e.g., thymus and spleen), histopathology, and hematological parameters remain useful, but more sophisticated techniques now augment these evaluations. Flow cytometry is widely employed to characterize immune cell subsets, quantify T- and B-cell populations, and detect activation markers. Cytokine profiling using multiplex ELISA or Luminex platforms allows quantification of inflammatory mediators, offering mechanistic insight into immune modulation.

Animal models have also evolved. In addition to standard rodent strains, immunodeficient and humanized mouse models are increasingly used to study xenografted immune cells or tumors in the context of drug treatment. These models allow researchers to evaluate cytokine release syndrome, immune cell depletion, or hyperactivation in vivo. The local immune microenvironment can be further probed using tissue-specific imaging or transcriptomic profiling.

Immunotoxicity studies are frequently integrated into repeated-dose toxicity protocols, but standalone immune function assays such as the T-cell-dependent antibody response (TDAR) remain a gold standard. TDAR measures the functional integrity of adaptive immunity by quantifying antibody production following exposure to a model antigen. Additional tests, such as delayed-type hypersensitivity assays, NK cell activity, and bone marrow cellularity evaluations, provide a comprehensive view of immune competence.

Regulatory agencies increasingly expect early immunotoxicity risk evaluation, especially for immune checkpoint inhibitors, monoclonal antibodies, and RNA-based therapeutics. The development of validated, mechanism-based in vivo models enhances the ability to anticipate adverse immune reactions and refine drug dosing strategies to mitigate risk.